ArticleTherapeutic advances in gastroenterology2026
Prevalence, patient characteristics, and outcomes of high-dose upadacitinib in inflammatory bowel disease.
Julian Azar et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.
1 paper cites it
this papercites it